HIGHLIGHTS
- who: Endry H. T. Lim from the Department of Intensive Care Medicine, Amsterdam UMC, Location AMC, Room, u2011421, Meibergdreef, AZ Amsterdam, The Netherlands have published the research: Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the PANAMO phase 2 trial, in the Journal: (JOURNAL) of April/24,/2020
- what: In the current substudy of the phase 2 PANAMO trial the authors aim to explore the effects of vilobelimab on various biomarkers of inflammation and coagulation. The aim was to explore . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.